Rome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review
Open Access
- 9 September 2026
- journal article
- review article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 662-669
Abstract
The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.Keywords
This publication has 28 references indexed in Scilit:
- Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical ApproachDigestive Diseases and Sciences, 2025
- Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trialJournal of Pediatric Gastroenterology and Nutrition, 2025
- Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysisThe Lancet Gastroenterology & Hepatology, 2025
- Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2023
- Physical activity for treatment of irritable bowel syndromeCochrane Database of Systematic Reviews, 2022
- Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysisThe Lancet Gastroenterology & Hepatology, 2020
- Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trialsAmerican Journal of Gastroenterology, 2018
- Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel SyndromeGastroenterology, 2016
- The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysisAmerican Journal of Gastroenterology, 2014